Safety, Tolerability, and Pharmacokinetics of FHND1002 Granules in Healthy Adults

Inclusion Criteria: * Aged ≥18 and ≤45 years, regardless of gender. * Male volunteers weigh ≥50 kg, and female volunteers weigh ≥45 kg, with a body mass index (BMI) between 19.0 and 26.0 kg/m² (inclusive). * Medical history, physical examination, laboratory tests, and other assessments are normal or clinically insignificant, as determined by the investigator. * Volunteers have no plans for pregnancy and voluntarily agree to use effective non-drug contraceptive measures (e.g., complete abstinence, condoms, sterilization) throughout the study and for three months after the last dose, with no plans for sperm or egg donation. * Volunteers agree to comply with all study procedures and follow-up schedules and provide written informed consent. Exclusion Criteria: * History or presence of gastrointestinal, renal, hepatic, pulmonary, neurological, hematological, endocrine, oncological, immunological, psychiatric, or cardiovascular diseases that, in the investigator's opinion, may affect the safety of the volunteer or study results. * History of severe allergies (e.g., angioedema or anaphylactic shock), hypersensitivity (e.g., to pollen or two or more drugs/foods), or known allergy to any components or excipients of the investigational drug. * Use of any drugs that inhibit or induce hepatic drug metabolism (e.g., barbiturates, carbamazepine, phenytoin, corticosteroids) within 28 days before screening. * Difficulty swallowing or a history of gastrointestinal diseases affecting drug a…